SYNTEX' ORAL CYTOVENE FOR CMV RETINITIS MAINTENANCE THERAPY APPROVED AS ALTERNATIVE TO INTRAVENOUS FORMULATION IN PATIENTS WITH STABILIZED DISEASE
Executive Summary
Syntex' oral Cytovene received FDA approval Dec. 22 as an alternative to Cytovene I.V. infusions, the company announced Jan. 5. The new formulation of Cytovene (ganciclovir capsules) is indicated for maintenance treatment of cytomegalovirus retinitis in immunocompromised patients, including those with AIDS, whose retinitis is stable following appropriate Cytovene I.V. (ganciclovir sodium) induction therapy.